First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis Medgenics, Inc. announced the launch of its Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients with end-stage renal disease on dialysis, through the sustained delivery of erythropoietin. [Medgenics, Inc.] Press Release Actinium Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Leukemia Trial of Actimab-A™ Actinium Pharmaceuticals, Inc. announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A™ in Acute Myeloid Leukemia clinical trial. [PR Newswire Association LLC] Press Release New Clinical Trial Seeks to Cure Advanced Crohn’s Disease by Replacing a Diseased Immune System with a Healthy One Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn’s disease. The initial goal of the Crohn’s Allogeneic Transplant Study is to treat a small number of patients with treatment-resistant Crohn’s disease by transplanting matched bone marrow cells from a sibling or unrelated donor. [Fred Hutchinson Cancer Research Center] Press Release Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia Trovagene, Inc. received notice of U.S. Patent 8,222,370. This is the first U.S. patent issued around nucleophosmin protein (NPM) mutations, and is part of a family of filed patents for Trovagene around NPMs. Mutation analysis of NPM1 is currently used for the diagnosis, stratification and monitoring of patients with acute myeloid leukemia. [PR Newswire Association LLC] Press Release Infinity Regains Worldwide Rights to PI3K, FAAH and Early Discovery Programs Infinity Pharmaceuticals, Inc. announced it has restructured its strategic alliance with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. by mutual agreement. With this restructuring, Infinity regains worldwide rights for its phosphoinositide-3-kinase (PI3K) program, its fatty acid amide hydrolase (FAAH) program and its early discovery programs. [Infinity Pharmaceuticals, Inc.] Press Release European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’s Sickle Cell Treatment Emmaus Medical, Inc. announced that the European Commission has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide for the treatment of sickle cell disease. [Emmaus Medical, Inc.] Press Release Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShield™ as a Treatment for Acute Radiation Syndrome Soligenix, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of OrbeShield™ as a treatment for gastrointestinal acute radiation syndrome (GI ARS). ARS occurs after toxic radiation exposure and involves several organ systems, notably the bone marrow and the GI tract. [PR Newswire Association LLC] Press Release |